Little Industry Criticism On FDA Radiation Rules Rewrite
Industry response to a US FDA overhaul of performance standards for some radiation-emitting devices is largely neutral to positive, a review of comments submitted by the 1 July deadline shows.
You may also be interested in...
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.
The US agency is relaxing some regulatory requirements on facial masks and actively pursuing ways to reprocess N95 respirators used by medical staff under an immediately-in-effect guidance document.